Benralizumab

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India

Conditions

In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India

Trial Timeline

Nov 19, 2021 → Jul 1, 2023

NCT ID

NCT05384938

About Benralizumab

Benralizumab is a approved stage product being developed by AstraZeneca for In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India. The current trial status is completed. This product is registered under clinical trial identifier NCT05384938. Target conditions include In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07444567	Phase 3	Recruiting	Mar 27, 2026	Dec 28, 2029	Asthma
NCT07214753	Pre-clinical	Recruiting	Dec 20, 2025	Dec 31, 2028	Severe Eosinophilic Asthma
NCT06512883	Phase 3	Recruiting	Apr 17, 2025	Apr 3, 2028	Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT06465485	Phase 3	Active	Feb 28, 2024	Dec 31, 2026	Severe Eosinophilic Asthma
NCT05273359	Phase 2	UNKNOWN	Apr 1, 2023	Jan 1, 2025	Chronic Obstructive Pulmonary Disease (COPD)
NCT05384938	Approved	Completed	Nov 19, 2021	Jul 1, 2023	In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
NCT05932849	Pre-clinical	Completed	Oct 5, 2021	Feb 28, 2022	Asthma
NCT04305405	Phase 3	Completed	Nov 21, 2019	Sep 12, 2022	Severe Uncontrolled Asthma
NCT04102800	Approved	Completed	Sep 30, 2019	Apr 23, 2024	Asthma
NCT03928262	Phase 1	Completed	Apr 2, 2019	Aug 12, 2019	Healthy Subjects
NCT03557307	Phase 3	Completed	Aug 1, 2018	Mar 24, 2022	Asthma
NCT03327701	Phase 3	UNKNOWN	Dec 1, 2017	Apr 1, 2020	Asthma, Exercise-Induced
NCT03010436	Phase 2	UNKNOWN	Apr 15, 2017	Dec 1, 2021	Asthma
NCT02918071	Phase 3	Completed	Nov 10, 2016	Aug 21, 2017	Asthma
NCT02869438	Phase 3	Completed	Nov 9, 2016	Aug 1, 2018	Asthma
NCT02821416	Phase 3	Completed	Oct 11, 2016	Oct 22, 2019	Asthma
NCT02417961	Phase 3	Completed	Apr 27, 2015	Mar 14, 2016	Asthma
NCT02130882	Phase 2/3	UNKNOWN	May 19, 2014	Dec 31, 2023	Respiratory System Agents

Competing Products

20 competing products in In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India

See all competitors

Product	Company	Stage	Hype Score
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	30
Daridorexant + Placebo	Idorsia	Phase 1	28
SON-1010 (IL12-FHAB)	Sonnet BioTherapeutics	Phase 1	28
Somatropin	Eli Lilly	Phase 3	77
agenT-797	MiNK Therapeutics	Phase 1	25
Pegilodecakin	Eli Lilly	Phase 1	33
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab	eFFECTOR Therapeutics	Phase 1/2	33
Lazertinib(G001) + Lazertinib(G002)	Yuhan	Phase 1	33
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	52
DJ-927 + capecitabine	Daiichi Sankyo	Phase 1	33
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Roxadustat	Astellas Pharma	Phase 1	33
ASP3325 + Placebo	Astellas Pharma	Phase 1	33
TRK-100STP	Astellas Pharma	Phase 1	33
Ensitrelvir	Shionogi	Phase 1	33
E6130 + Placebo	Eisai	Phase 1	33
E7389 + E7389 + E7389	Eisai	Phase 1	33
Eribulin Mesylate	Eisai	Phase 1	33
E2022 + E2022 + E2022 + E2022 + E2022	Eisai	Phase 1	33
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride	Eisai	Phase 1	33

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved